title: Adalimumab in psoriatic arthritis.
abstract: Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease, enthesitis, and dactylitis. ADA significantly inhibited structural changes on radiographs, lessened disability, and improved quality of life in patients with active PsA. One study showed the efficacy of 24-week ADA therapy on bone marrow edema and erosions, as measured by magnetic resonance imaging. The clinical and radiographic efficacy of ADA demonstrated during short-term treatment was sustained during longterm treatment. ADA was generally well tolerated and its safety profile was similar to that reported in studies of ADA in rheumatoid arthritis. Overall, ADA has a favorable risk-benefit profile in PsA. The combination of ADA and cyclosporine seems to be more effective than ADA monotherapy in patients with active PsA and inadequate response to methotrexate; however, this observation must be confirmed in RCT.
authors: Rheumatology Unit, Azienda Ospedaliera ASMN, IRCCS, Reggio Emilia, Italy. salvarani.carlo@asmn.re.it
authors: Carlo
authors: C
authors: Salvarani
authors: Nicolò
authors: N
authors: Pipitone
authors: Mariagrazia
authors: M
authors: Catanoso
authors: Ilaria
authors: I
authors: Chiarolanza
authors: Luigi
authors: L
authors: Boiardi
authors: Andrea
authors: A
authors: Caruso
authors: Giulia
authors: G
authors: Pazzola
authors: Pierluigi
authors: P
authors: Macchioni
authors: Vito
authors: V
authors: Di Lernia
authors: Giuseppe
authors: G
authors: Albertini
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D019317:Evidence-Based Medicine; D006801:Humans; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab